Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors

Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic strategy for targeted protein degradation. However, the clinical application of PROTACs may be hindered by off-target toxicity resulting from non-tissue-specific protein degradation and ingenious prodrug strategies may open new avenues to addressing this concern. Herein, we propose a light-induced positive feedback strategy to use photodynamic therapy (PDT) to improve the activation efficiency of PROTAC prodrugs, monitor PROTAC release, and combine PROTAC to induce tumor cell apoptosis. In the hypoxic tumor microenvironment, the azo bond in AZO-PRO selectively cleaves, triggering the release of the potent protein degrader PRO and the multifunctional photosensitizer. Once activated, the fluoresce signal of the photosensitizer dramatically recovers, allowing monitoring of prodrug activation. Additionally, upon irradicating the tumor site using near-infrared (NIR) laser, PDT exacerbates tumor hypoxia, further promoting AZO-PRO activation. Our work introduces a novel approach to efficiently track and activate PROTAC prodrugs, enhance their antitumor efficacy, and mitigate off-target systemic toxicity.

Authors

Institutions

Publication Details

Journal
Acta Pharmaceutica Sinica B
Published
2025-07-15
DOI
https://doi.org/10.1016/j.apsb.2025.07.020
Citations
8
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
6.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors

Yuchen Yang, Hong‐Wei Hou, Meichen Pan, Zhongliang Fu et al.
8 citations
Acta Pharmaceutica Sinica B
Protein Degradation and Inhibitors
6.45
article

Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors

Yuchen Yang, Hong‐Wei Hou, Meichen Pan, Zhongliang Fu, Jinghong Li, Chunrong Yang
article en
8 citations

Abstract

Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic strategy for targeted protein degradation. However, the clinical application of PROTACs may be hindered by off-target toxicity resulting from non-tissue-specific protein degradation and ingenious prodrug strategies may open new avenues to addressing this concern. Herein, we propose a light-induced positive feedback strategy to use photodynamic therapy (PDT) to improve the activation efficiency of PROTAC prodrugs, monitor PROTAC release, and combine PROTAC to induce tumor cell apoptosis. In the hypoxic tumor microenvironment, the azo bond in AZO-PRO selectively cleaves, triggering the release of the potent protein degrader PRO and the multifunctional photosensitizer. Once activated, the fluoresce signal of the photosensitizer dramatically recovers, allowing monitoring of prodrug activation. Additionally, upon irradicating the tumor site using near-infrared (NIR) laser, PDT exacerbates tumor hypoxia, further promoting AZO-PRO activation. Our work introduces a novel approach to efficiently track and activate PROTAC prodrugs, enhance their antitumor efficacy, and mitigate off-target systemic toxicity.

Acta Pharmaceutica Sinica BVol. 15(9)
University of Science and Technology of China (CN), Hunan University (CN), Hefei National Center for Physical Sciences at Nanoscale (CN), Beijing Academy of Science and Technology (CN), Tsinghua University (CN)
Openalex Percentile: Top 3%
Protein Degradation and Inhibitors
6.45
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors — Yuchen Yang, Hong‐Wei Hou, et al. · Acta Pharmaceutica Sinica B (2025) | TGRS Research Map | TGRS